Attached files
SEGMENT INFORMATION
TECHNE CORPORATION AND SUBISIDARIES
(in thousands of $'s, except per share data)
Fiscal 2012 Increase (Decrease) From Fiscal 2011
-------------------------------------------------- ---------------------------------------
First Second Third Fourth Percent First Second Third Fourth
Quarter Quarter Quarter Quarter YTD of Sales Quarter Quarter Quarter Quarter YTD
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Sales 77,596 74,662 83,621 78,681 314,560 100% 9,651 6,954 7,350 643 24,598
Cost of sales 19,209 19,492 20,238 19,817 78,756 25% 3,859 4,165 4,297 1,410 13,731
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin 58,387 55,170 63,383 58,864 235,804 75% 5,792 2,789 3,053 (767) 10,867
Gross margin
percentage 75.2% 73.9% 75.8% 74.8% 75.0%
SG&A expense 10,773 10,651 9,899 10,360 41,683 13% 3,160 2,224 604 (202) 5,786
R&D expense 6,667 6,837 7,122 7,286 27,912 9% 48 234 825 820 1,927
Interest income (728) (798) (470) (643) (2,639) (1%) 119 222 597 175 1,113
Impairment loss 0 0 3,254 0 3,254 1% 0 0 3,254 0 3,254
Other non-oper-
ating ex., net 1,175 607 373 1,244 3,399 1% 918 (91) (48) 794 1,573
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
17,887 17,297 20,178 18,247 73,609 23% 4,245 2,589 5,232 1,587 13,653
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Earnings before
income taxes 40,500 37,873 43,205 40,617 162,195 52% 1,547 200 (2,179) (2,354) (2,786)
Income taxes 12,979 12,060 11,449 13,376 49,864 16% 399 921 (2,871) (1,264) (2,815)
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
27,521 25,813 31,756 27,241 112,331 36% 1,148 (721) 692 (1,090) 29
======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======
Diluted earnings
per share 0.74 0.70 0.86 0.74 3.04
Weighted average
diluted shares
outstanding 37,170 37,028 36,930 36,894 37,006
BIOTECHNOLOGY (1)
(in thousands of $'s)
Fiscal 2012 Increase (Decrease) From Fiscal 2011
-------------------------------------------------- ---------------------------------------
First Second Third Fourth Percent First Second Third Fourth
Quarter Quarter Quarter Quarter YTD of Sales Quarter Quarter Quarter Quarter YTD
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Sales 72,303 69,808 78,180 72,983 293,274 100% 9,262 6,728 7,060 (63) 22,987
Cost of sales 16,465 16,887 17,444 17,014 67,810 23% 3,624 4,267 4,145 1,185 13,221
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin 55,838 52,921 60,736 55,969 225,464 77% 5,638 2,461 2,915 (1,248) 9,766
Gross margin
percentage 77.2% 75.8% 77.7% 76.7% 76.9%
SG&A expense 9,470 9,003 8,921 9,059 36,453 12% 2,984 2,144 995 272 6,395
R&D expense 6,469 6,624 6,924 7,095 27,112 9% 48 245 820 823 1,936
Interest income (609) (689) (387) (541) (2,226) (1%) 53 129 484 132 798
Exchange loss/
gain 524 105 (164) 897 1,362 0% 1,029 18 85 1,074 2,206
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
15,854 15,043 15,294 16,510 62,701 21% 4,114 2,536 2,384 2,301 11,335
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Pretax result 39,984 37,878 45,442 39,459 162,763 56% 1,524 (75) 531 (3,549) (1,569)
======= ======= ======= ======= ======== ======== ======= ======= ======= ======= ======
(1) Includes R&D Systems Biotechnology Division, R&D Systems Europe,
BiosPacific, R&D China, Boston Biochem and Tocris.
HEMATOLOGY
(in thousands of $'s)
Fiscal 2012 Increase (Decrease) From Fiscal 2011
-------------------------------------------------- ---------------------------------------
First Second Third Fourth Percent First Second Third Fourth
Quarter Quarter Quarter Quarter YTD of Sales Quarter Quarter Quarter Quarter YTD
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Sales 5,293 4,854 5,441 5,698 21,286 100% 389 226 290 706 1,611
Cost of sales 2,744 2,605 2,794 2,803 10,946 51% 235 (102) 152 225 510
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin 2,549 2,249 2,647 2,895 10,340 49% 154 328 138 481 1,101
Gross margin
percentage 48.2% 46.3% 48.7% 50.8% 48.6%
SG&A expense 480 400 435 382 1,697 8% 152 64 (3) 33 246
R&D expense 198 213 198 191 800 4% -- (11) 5 (3) (9)
Interest income (47) (45) (23) (44) (159) (1%) 6 21 46 11 84
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
631 568 610 529 2,338 11% 158 74 48 41 321
------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Pretax result 1,918 1,681 2,037 2,366 8,002 38% (4) 254 90 440 780
======= ======= ======= ======= ======== ======== ======= ======= ======= ======= ======
CORPORATE AND OTHER (2)
(in thousands of $'s)
Fiscal 2012 Increase (Decrease) From Fiscal 2011
---------------------------------------- ---------------------------------------
First Second Third Fourth First Second Third Fourth
Quarter Quarter Quarter Quarter YTD Quarter Quarter Quarter Quarter YTD
------- ------- ------- ------- ------- ------- ------- ------- ------- ------
Interest income 72 64 60 58 254 (60) (72) (67) (32) (231)
Rental income 134 198 150 211 693 11 60 36 37 144
------- ------- ------- ------- ------- ------- ------- ------- ------- ------
206 262 210 269 947 (49) (12) (31) 5 (87)
SG&A expense 823 1,248 543 919 3,533 24 16 (388) (507) (855)
Other-Building
expenses 587 482 545 513 2,127 31 (49) (41) (107) (166)
Other-Impairment
losses 0 0 3,254 0 3,254 0 0 3,254 0 3,254
Other-Equity
investment losses 198 218 142 45 603 (131) 0 (56) (136) (323)
------- ------- ------- ------- ------- ------- ------- ------- ------- ------
1,608 1,948 4,484 1,477 9,517 (76) (33) 2,769 (750) 1,910
------- ------- ------- ------- ------- ------- ------- ------- ------- ------
Pretax result (1,402) (1,686) (4,274) (1,208) (8,570) 27 21 (2,800) 755 (1,997)
======= ======= ======= ======= ======= ======= ======= ======= ======= ======
(2) Unallocated corporate expenses and Techne's share of losses
by Hemerus Medical, LLC and Nephromics, LLC
